On the contrary, when AVPR1a is blocked by selective antagonists such as relcovaptan or tumor cells are exposed to specific AVPR2 agonists such as desmopressin, significant antiproliferative effects are achievable in hormone-resistant breast cancer cell lines (10, 11). This evidence concerns the gene AVPR2 and neoplasm.